Law firm says Insulet investors may seek lead plaintiff role in securities suit
Glancy Prongay Wolke & Rotter LLP says investors with losses in Insulet Corporation may move to lead a securities fraud class action before an Aug. 31 deadline.
A law firm says Insulet investors who lost money may seek lead-plaintiff status in a securities fraud class action tied to alleged manufacturing-control failures and safety risks.
Glancy Prongay Wolke & Rotter LLP said in an Aug. 11, 2026, press release that investors with losses in Insulet Corporation may seek appointment as lead plaintiff in a securities fraud class action. The release says the deadline to move for lead-plaintiff status is Aug. 31, 2026.
The firm said the complaint covers a period from Feb. 21, 2025, through May 26, 2026. It alleges that Insulet and related defendants made materially false and/or misleading statements and failed to disclose adverse facts about the company’s business, operations and prospects.
According to the release, the complaint alleges Insulet’s manufacturing controls and procedures were defective. It also alleges those controls created a foreseeable heightened risk that one or more Insulet products could violate safety regulations or pose a risk of injury.
The release says the company’s positive statements were materially misleading and/or lacked a reasonable basis at the time. It also says no class has been certified yet.
Insulet Corporation, which trades under the ticker PODD, is the company named in the press release. The firm said investors may retain counsel of their choice or take no action and remain absent class members.
The press release gives investors until Aug. 31, 2026, to seek lead-plaintiff appointment. It also lists contact information for Glancy Prongay Wolke & Rotter LLP in Los Angeles.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()